Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vestas secures 140 MW order from Capital Power in Canada

News release from Vestas-American Wind TechnologyPortland, August 15, 2023 Vestas has received a 140 MW order to power the Halkirk II wind project owned by Capital Power in Alberta, Canada. The order consists of 31 V150-4.5 MW wind turbines. The order includes supply, delivery, and commissioning of the turbines, as well as a 10-year Active Output Management 5000 (AOM 5000) service agreement, designed to ensure optimised performance of the asset. “We’re thrilled to partner again with Capital Power to expand their wind energy portfolios in Canada, particularly with one of the

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 116 - 15 AUGUST 2023  In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 112/23 and 113/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Invitation to presentation of Q2 2023

Concordia Maritime invites to teleconference/audio transmission on 24 August 2023 at 14.00 CEST. The session will feature a presentation of the Q2 2023 interim report and a Q&A session.If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions. https://ir.financialhearings.com/concordia-maritime-q2-report-2023 If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the

Heart Aerospace announces Director of Government & Industry Affairs

Swedish electric airplane maker Heart Aerospace is pleased to announce Simon McNamara as its Director of Government and Industry Affairs.With more than 25 years of experience in aviation public affairs, much of it focused around the regional airline sector, Simon brings considerable advocacy expertise to Heart.  For the past five years Simon has been leading advocacy efforts in the UK and Ireland for the International Air Transport Association (IATA) with much of the work focused on sustainability issues.    “I’m very pleased to welcome Simon to the team. Decarbonizing air travel

Tibnor plans to adjust cost structure

SSAB’s subsidiary Tibnor plans to adjust operations due to lower demand and profitability. The measures aim at annual costs savings of approximately SEK 150 million and cover all Tibnor business areas and countries with the exception of the Baltic countries. The plan is to implement the measures in the fall of 2023, and this may result in the staff reduction of approximately 175 positions.Tibnor aims to improve the operating efficiency by adjusting the company's cost structure and streamlining the organization. At the same time, the aim is to ensure the conditions to implement the company's

BioStock: Elicera's potential in cancer therapy published in Nature Communications

Elicera Therapeutics uses CAR T-cells as a basis for two of its four cancer immunotherapy programmes. The ELC-401 programme addresses challenges in treating solid tumours, glioblastoma specifically, where the microenvironment is extremely hostile to immunotherapies. Through a recent article published in Nature Communications, Elicera sheds light on the potential of the CAR T construct used within ELC-401.Read the article at biostock.se: Elicera's potential in cancer therapy published in Nature Communications - BioStock 

Interim report January-June 2023

Completed rights issue and investments in new technologyIn July, the rights issue resolved upon by the Annual General Meeting on June 16, 2023, was completed. The issue was 71.3 percent guaranteed, but only a smaller percentage (about 1 percent) of the guarantors received allotment. Through the rights issue, the company raised MSEK 54.8 before issuance costs, which means that the planned repayment of bridging loans proceeds while we pursue a long-term plan for financing of future initiatives and operating capital. Net sales decreased during the quarter, to MSEK 18.8 (24.1). The lower net

Interim report January–June 2023

Strong growth in GARO E-mobility but more tentative in GARO Electrification APRIL–JUNE 2023 · Net sales amounted to MSEK 386.0 (350.2). · Net sales increased 10% (3). · EBIT amounted to MSEK 18.2 (39.6). · EBIT margin amounted to 4.7% (11.3). · Net income was MSEK 20.1 (33.3). · Earnings per share amounted to SEK 0.40 (0.67). JANUARY–JUNE 2023 · Net sales amounted to MSEK 756.3 (731.8). · Net sales increased 3% (16). · EBIT amounted to MSEK 45.9 (106.4). · EBIT margin amounted to 6.1% (14.5). · Net income was MSEK 40.6 (87.1). · Earnings per

Changes in the Group Executive Management Team

AFRY is making changes to the Group Executive Management team to strengthen profitability in line with the company's business strategy and financial targets. Robert Larsson becomes EVP and Head of Division Infrastructure and Martin Öman EVP and Head of Division Industrial & Digital Solutions. The changes will take effect on September 1, 2023.Robert Larsson has been appointed as EVP and Head of Division Infrastructure to increase profitability and develop the business in the division. Robert has been a member of AFRY's Group Executive Management and Head of Division Industrial & Digital

Dicot has received approval to start phase 1 clinical trial

Press release: Uppsala, August 15, 2023. Dicot announces that the Swedish Medical Products Agency has granted permission to start clinical phase 1 trial with the drug candidate LIB-01. It is a placebo-controlled trial with primary objective to evaluate the safety profile in humans.Dicot's first-in-human study of the potency drug candidate LIB-01 has now received permission to start from the Swedish Medical Products Agency. Approval from the Ethics Review Authority has also been obtained and other preparations are complete. Screening of participants and dosing of the first dose group will

Quickbit eu AB (publ) carries out a rights issue of SEK 32.5 million

The board of Quickbit eu AB (publ) ("Quickbit" or the "Company") has, with the support of authorization from the annual general meeting on November 22, 2022, decided to carry out an issue of shares with preferential rights for existing shareholders (the "Rights Issue"). The subscription period runs during the period 29 September – 13 October 2023. The subscription price amounts to SEK 0.41 per share. Through the Rights Issue, the Company will receive up to approximately SEK 32.5 million before issue costs. The Rights Issue is covered by subscription obligations and underwriting guarantees of

BioStock: Arcede hopes to reach larger market than existing drugs

Lund-based Arcede Pharma quietly been working away on the drug candidate RCD405 during the second quarter. The second part of the toxicology study is now underway, while the company is continuing preparations for the future beyond preclinical development. BioStock contacted CEO Mia Lundblad to find out more about what is happening in the company.Read the full article at biostock.se : https://www.biostock.se/en/2023/08/arcede-hopes-to-reach-larger-market-than-existing-drugs/ This is a press release from BioStock - Connecting Innovation & Capital. https://

Catena Media announces share buybacks executed from 7 to 11 August 2023

Catena Media plc (LEI code: 549300609A73DL5C5Z86) repurchased 167,053 of its own ordinary shares (ISIN code: MT0001000109) from 7 to 11 August 2023 as part of its share buyback programme. The buyback programme was authorised by shareholders at an extraordinary general meeting on 12 July 2023 and initiated and announced by the board of directors on 17 July 2023. The programme is being carried out in accordance with the EU Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) 2016/1052 (the "Safe Harbour Regulation"). Its purpose is to deliver

Two Instalco companies in renovation assignment in Östersund

The Instalco companies, RP Montage & Energipartner and TC Kraft have won a joint assignment for installation of the heating & plumbing and electrical installations associated with major renovation work for around 200 apartments in Östersund. They have been engaged by NCC for this assignment, where the end customer is Östersundshem. The order value is approximately SEK 50 million.“We are delighted to be continuing our collaboration with NCC and Östersundshem and that we are two Instalco companies that have been selected for one of Jämtland’s major ROT (tax deduction) renovation projects. By

Everysport Group divests a media portfolio valued at SEK 45 million

Everysport Group AB (publ) ("Everysport") has today entered into an agreement with Better Collective A/S to divest a portfolio consisting of the brands and media sites SvenskaFans , Hockeysverige , FotbollDirekt  and Innebandymagazinet  (together the "Media Portfolio"). The transaction is carried out at a valuation of the Media portfolio of approximately SEK 45 million (EUR 3.8 million). The total purchase price, after deduction of certain working capital items, amounts to

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon[®] (TARPEYO[®] (budesonide) delayed release capsules/Kinpeygo[®]) in adults with Primary IgA nephropathy (IgAN). The Phase 3 trial met the primary endpoint, estimated glomerular filtration rate (eGFR), with Nefecon demonstrating significant kidney protective effect over placebo.“IgAN is a severe debilitating disease leading to end-stage kidney disease in more than 50% of the patients. The full results from

atNorth Announces Erling Gudmundsson as COO as Expansion Continues

Infrastructure veteran strengthens the Executive Team as the business experiences significant growth.Reykjavík, Iceland – August 15[th], 2023 –  atNorth,  a leading Nordic colocation, high-performance computing, and artificial intelligence service provider, has announced the appointment of Erling Gudmundsson as Chief Operating Officer (COO). The hire supports atNorth’s commitment to building a world class leadership team to guide its extensive growth plans in response to the increasing demand for cost efficient and sustainable digital

Alligo’s Board of Directors has decided to repurchase own shares

The Board of Directors of Alligo AB (publ) has through the authorization given by Annual General Meeting held on 24 May 2023, decided to repurchase its own Class B shares.The aim of the repurchase is to enable financing of future acquisitions of companies or businesses with own shares and to adapt the Group’s capital structure. The shares will be repurchased, on one or several occasions, continuously until the AGM 2024. The shares will be repurchased on Nasdaq Stockholm according to the Nordic Main Market Rulebook for Issuers of Shares. In accordance with the Board’s decision, the

Esmaeilzadeh Holding publishes net asset value as of 31 July 2023

As of 31 July 2023, the net asset value for Esmaeilzadeh Holding AB (publ) was SEK 7.88 billion (SEK 7.89 billion as of 30 June 2023), corresponding to a net asset value per share of SEK 10,222 (SEK 10,240 as of 30 June 2023). For further information, please contact: Saeid Esmaeilzadeh, CEO and founder saeid@ehab.group Nils Fredrik Lagerstrand, General Counsel & Deputy CEO +46 720 90 26 99, nilsfredrik@ehab.group The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 15 August 2023. About Esmaeilzadeh

Repurchases of shares by Concentric AB during week 32, 2023

Between 7 August 2023 and 11 August 2023 Concentric AB (LEI code 5493002G9GMTKIP3PW19) (“Concentric”) has repurchased in total 10,198 own shares (ISIN: SE0003950864) as part of the repurchase program initiated by the Board. The repurchases form part of the repurchase program of a maximum of 3,519,172 own shares for a total maximum amount of SEK 150,000,000 that Concentric announced on 26 July 2023. The repurchase program, which runs between 31 July 2023 and 31 March 2024, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 and the Commission Delegated

Invitation to presentation of Ranplan’s H1 interim report 2023

Stockholm, Sweden, 15 August 2023 Ranplan Group AB is pleased to invite media, investors, shareholders and financial analysts to a video conference meeting from its office in the city of Stockholm. On this occasion, CEO Per Lindberg and CSO Jon Ullmark will present the report for the first six months of 2023. Those who want to participate online at this event should notify the company of their interest before 6pm CET on 23 Aug 2023 by sending an e-mail to joyce.wu@ranplanwireless.com. On the morning of 24 Aug 2023, registered parties will receive an email with a link to the call.

First Camp Group Interim report Q2 2023

First Camp, Scandinavia’s largest campsite chain, increased revenues in the second quarter of 2023 by 18 percent vs same period in 2022. Revenue adjusted for effects from acquisitions (pro forma) increased with four percent vs same period in 2022.Second quarter 2023 (same quarter last year in brackets) · Total revenue of SEK 285.5 million (242.4) · Pro forma revenue increased with 4% compared to Q2 2022 · Pro forma Adjusted EBITDA amounted to SEK 38.6 million (40.9) · EBIT of SEK -4.7 million (-29.5) · Cash flow from operating activities of SEK 121.3 million (137.3) ·

Production of renewable diesel restarted at the expanded part of Neste’s Singapore refinery after operational shutdown

Neste Corporation, Press Release, 15 August 2023 at 9 a.m. (EET)The production of renewable diesel at Neste’s Singapore refinery expansion has been restarted in early August according to the company’s plans. The production line at the expanded part of the refinery was shut down in June for unexpected equipment repairs. The ramp-up of the production at the expanded part of the refinery continues and is planned to be completed by the end of the year. SAF production in Singapore is scheduled to start during the third quarter as communicated in Neste’s half-year report in July.

Capnor Weasel Bidco Oyj, Half Year Financial Report, January – June 2023

Half Year Financial Report 2023 Second quarter highlights · Revenue increased by 1% to MEUR 29.1 (28.8) · EBITDA decreased to MEUR 2.8 (4.7), corresponding to a 10% (16%) EBITDA margin · EBIT decreased to MEUR 0.3 (2.4), corresponding to a 1% (8%) EBIT margin · Operational Cash Flow was negative at MEUR-6.9 (+0.4) Significant events during the quarter · Market entry to the US is on schedule and progressing as planned · iLOQ to partner up with Genetec to create secure and streamlined access management solutions · iLOQ announced that Tierps Energi och Miljö AB

There are no items matching the current filter
There are no more items matching the current filter
Back to top